drugset / Trial / NCT05797168
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Timeline
- Start
- 2023-06-05
- Primary completion
- 2028-01-06
- Completion
- 2028-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5335 | Unknown | — | Intravenous |
| Subject | AZD9574 | Small molecule | — | Oral |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Saruparib | Small molecule | — | Oral |